Sex differences in lithium concentrations among bipolar patients with different episodes based on real-world therapeutic monitoring data
- PMID: 40596962
- PMCID: PMC12219772
- DOI: 10.1186/s12888-025-07111-9
Sex differences in lithium concentrations among bipolar patients with different episodes based on real-world therapeutic monitoring data
Abstract
Background: Sex differences in lithium-associated efficacy and adverse events have been well studied in bipolar disorder. Exploring variations in lithium concentrations between sexes may offer potential explanations.
Methods: This multicenter, real-world, observational study, which was based on therapeutic monitoring data, was conducted at six Chinese hospitals. Sex differences in lithium concentrations and potential affecting factors were explored using the generalized estimating equation and multiple linear regression analysis, respectively.
Results: A total of 525 bipolar patients were included, comprising 328 patients diagnosed with mania or mania with depressive features and 197 with bipolar depression. There were 398 females and 127 males, including 79 patients aged 13-17 years. The median final lithium dosage of all the subjects was 0.9 g per day, with an average final concentration of 0.68 mmol/L. The lithium concentration was relatively stable in the context of a fixed dosage. In patients with mania or mixed features, lithium concentrations in females were significantly higher than those in males when a fixed lithium dosage was administered. This phenomenon was not observed in patients with bipolar depression. The number of factors influencing lithium concentrations was greater for males with mania or mixed features than for females, which was not observed between males and females with bipolar depression.
Conclusions: The therapeutic lithium concentrations of bipolar male and female patients in real-world clinical practice were lower than the guideline-recommended ranges. In patients with manic or mixed features, females have a greater propensity for lithium accumulation than males do, and lithium concentrations are more likely to be affected by internal and external changes in males than in females. Therefore, the potential risk of toxicity and the stability of lithium concentrations are key points in females and males on lithium therapy, respectively.
Keywords: Bipolar disorder; Concentration; Lithium; Sex.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The Ethics Committees of all the participating centers reviewed and approved the study protocol, including Shenzhen Kangning Hospital (leading research center, approval no. 2020-K025-01-1, 2020-K025-02); The Second Xiangya Hospital of Central South University (approval no. 2020-144); Nanjing Brain Hospital (approval no. 2020-KY210-01); Tianjin Anding Hospital (approval no. 2021-01); Huzhou Third Municipal Hospital (approval no. 2020-108); and Shanghai Hongkou Mental Health Center (deceleration of ethics approval: study can be started upon the leading research center passing ethics approval). Written informed consent was required for participation in the study. Consent for publication: All authors agreed on the publication of this work and are accountable for all aspects of the work. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.
Figures
Similar articles
-
Oxcarbazepine for acute affective episodes in bipolar disorder.Cochrane Database Syst Rev. 2011 Dec 7;(12):CD004857. doi: 10.1002/14651858.CD004857.pub2. Cochrane Database Syst Rev. 2011. PMID: 22161387
-
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. doi: 10.3310/hta8190. Health Technol Assess. 2004. PMID: 15147609
-
Lithium for maintenance treatment of mood disorders.Cochrane Database Syst Rev. 2001;(3):CD003013. doi: 10.1002/14651858.CD003013. Cochrane Database Syst Rev. 2001. PMID: 11687035
-
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. doi: 10.3310/hta11390. Health Technol Assess. 2007. PMID: 17903393
-
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.Cochrane Database Syst Rev. 2001;(3):CD003196. doi: 10.1002/14651858.CD003196. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2013 Oct 17;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. PMID: 11687047 Updated.
References
-
- Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, Hopwood M, Lyndon B, Mulder R, Porter R, et al. The 2020 Royal Australian and new Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7–117. - PubMed
-
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. - PMC - PubMed
-
- Wang Z, Chen J, Yang H, Ma Y, Meron D, Liu T, Yu X, Fang Y. Assessment and management of bipolar disorder: principal summary of updated Chinese guidelines. Bipolar Disord. 2018;20(3):289–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical